EGFR and breast carcinoma: Given the heterogeneity of breast cancer cells, it is plausible to suggest that the different outcomes of AnxA6 modulation of EGFR in MDA-MB-231 cells and BT-549 cells are cell type specific and presumably dictated by the level of AnxA6 expression.